A novel robotic wastewater analysis system to quantify opioid exposure and treatment in residential communities

一种新型机器人废水分析系统，用于量化住宅社区中阿片类药物的暴露和处理

• 批准号: 10313450
• 负责人: Peter R Chai
• 金额: $ 54.91万
• 依托单位: BIOBOT ANALYTICS, INC.
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-04-15 至 2022-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10313450
• 关键词: Address; Adopted; Adoption; Algorithms; American; Benchmarking; Biological Markers; Boston; Buprenorphine; Cessation of life; Cities; Code; Collaborations; Collection; Communities; Data; Data Analytics; Data Set; Data Sources; Death Rate; Detection; Development; Devices; Drops; Drug Exposure; Drug usage; Ensure; Epidemic; Feedback; Fentanyl; Geography; Goals; Gold; Government; Government Officials; Grant; Heroin; High Pressure Liquid Chromatography; Hospitals; Hour; Human; Illicit Drugs; Infrastructure; Intervention; Massachusetts; Measures; Medical emergency; Methadone; Methods; Modeling; Modification; Morbidity - disease rate; Municipalities; Naloxone; Naltrexone; Neighborhoods; North Carolina; Opioid; Overdose; Parents; Pattern; Pharmaceutical Preparations; Phase; Pilot Projects; Plants; Policies; Population; Public Health; Publishing; Rain; Recording of previous events; Reporting; Resolution; Robotics; Sampling; Site; Small Business Innovation Research Grant; Sufentanil; System; Systems Analysis; Techniques; Technology; Testing; Time; United States; Update; Urine; Visualization; Weather; Woman; analog; base; dashboard; data analysis pipeline; data visualization; design; falls; health data; illicit opioid; improved; innovation; insight; instrument; interest; medical schools; models and simulation; novel; online version; opioid abuse; opioid epidemic; opioid exposure; opioid overdose; opioid use; opioid use disorder; outreach; overdose death; prescription opioid; response; sample collection; success; tool; urinary; wastewater sampling; wastewater testing

Project Summary This proposed Phase I/Phase II FastTrack SBIR project will lead to the demonstration of a robust wastewater testing and analytics platform that government stakeholders can use to guide localized actions to respond to the opioid epidemic. The opioid epidemic is the biggest drug crisis in American history, resulting in over 130 deaths every day. Currently, stakeholders use overdose death data to guide their opioid response strategies. However, this data is infrequently updated, often aggregated at geographic levels which are too large to be actionable by public health officials, and rarely provides insight into specific drug types (e.g. prescription vs. illicit opioids, fentanyl, etc.). Novel data sources which provide localized, real-time, and drug-specific insights are needed to inform response efforts in this rapidly changing epidemic. Wastewater-based testing is a promising approach for measuring population-level drug exposure, but has significant technical limitations before it can be useful to stakeholders on the frontlines of the epidemic. Specifically, current wastewater testing approaches rely on sampling at wastewater treatment plants, which yields city-level data at best. This represents a heterogenous sample and is not useful to guide localized interventions. Biobot is the first commercial wastewater testing technology designed and built to provide actionable public health insights for municipal stakeholders tackling the opioid epidemic. Our robotic wastewater analysis system measures opioid exposure and treatment (distinguishing human use from discarding in the toilet), and operates at the neighborhood-level — the geographic resolution relevant to municipal stakeholders. The premiere version of our platform includes (1) an algorithm to select sampling sites (manholes) that represent residential communities in a municipality; (2) a robotic sampling device that can be installed under sewer access portals (e.g. manhole covers) to collect 24-hour composite samples; (3) a HPLC-MS/MS method that detects a variety of urinary metabolites of prescription opioids, methadone, buprenorphine, and naloxone; and (4) visualization in printed reports. The goal of this Fast Track Phase I/Phase II application is to improve our platform to make it adoptable in cities across the nation. In collaboration with leading toxicologists at Brigham and Women’s Hospital and Harvard Medical School, we will address technological gaps to improve data reliability and move from detection to consistent quantification of opioid exposure and treatment. In Phase I, we will improve and expand our HPLC-MS/MS method, develop simulation models to optimize sample collection, and address the variability challenge of 24-hour sampling. In Phase II, we will develop data correction methods to enable integration with all existing sewer infrastructures, validate our data against reported overdoses in a pilot study across six Massachusetts municipalities, and build a data analytics and visualization platform for our end users. Successful completion of the proposed project will lead to an optimized and validated wastewater testing technology that provides accurate, spatially granular, and more real-time data on opioid exposure and treatment. In parallel with the technological development, this grant will allow us to demonstrate the value of our product to two key customers: the City of Boston and the State of Massachusetts. These two government organizations are key champions to pave the way for long-term adoption by our target customers.

项目摘要 该提议的I阶段I/II期FastTrack SBIR项目将导致演示 政府利益相关者可以用来指导的强大废水测试和分析平台 对阿片类药物流行反应的局部行动。阿片类药物流行是最大的药物 美国历史上的危机，每天导致130多人死亡。目前，利益相关者使用 过量的死亡数据指导其阿片类药物反应策略。但是，此数据很少 更新，通常在地理层面上汇总，这些层面太大而无法公开采取行动 卫生官员，很少提供对特定毒品类型的见解（例如，处方与非法 阿片类药物，芬太尼等）。提供局部，实时和特定药物的新型数据源 需要见解以告知这种迅速变化的流行病的响应工作。 基于废水的测试是测量人群水平药物的一种有前途的方法 接触，但具有重大的技术限制，然后才能对利益相关者有用 流行病的前线。具体而言，当前的废水测试方法依赖于抽样 在废水处理厂，充其量可以产生城市级别的数据。这代表 异源样本，对于指导局部干预措施没有用。 Biobot是第一个设计和建造的商业废水测试技术 可行的公共卫生洞察力针对市利益相关者应对OID流行病。我们的 机器人废水分析系统测量OIOID暴露和治疗（区分 人类从丢弃厕所中使用），并在社区层面上运作 - 与市政利益相关者有关的地理决议。我们平台的首映版本 包括（1）算法选择代表居民的采样位点（人孔） 市政当局的社区； （2）可以在下水道下安装的机器人抽样设备 访问门户（例如人孔盖）收集24小时复合样品； （3）HPLC-MS/MS 检测各种处方阿片类药物的尿代谢物，美沙酮， 丁丙诺啡和纳洛酮； （4）印刷报告中的可视化。 这个快速轨道I/II阶段应用程序的目标是改善我们的平台以实现它 可在全国各地的城市采用。与Brigham的领先毒理学家合作 妇女医院和哈佛医学院，我们将解决技术空白以改善 数据可靠性并从检测到一致的阿片类药物暴露和 治疗。在第一阶段，我们将改进和扩展我们的HPLC-MS/MS方法，开发 仿真模型优化样本收集，并应对的可变性挑战 24小时采样。在第二阶段，我们将开发数据校正方法以启用集成 使用所有现有的下水道基础设施，请验证我们的数据，以针对飞行员中的过量剂量验证 在马萨诸塞州六个市政当局进行研究，并建立数据分析和可视化 最终用户的平台。 拟议项目的成功完成将导致经过优化和验证 废水测试技术可提供准确的，空间颗粒状的和更实时的 有关阿片类药物暴露和治疗的数据。与技术发展并行，这笔赠款 将使我们能够向两个主要客户展示产品的价值：波士顿市 和马萨诸塞州。这两个政府组织是 为我们的目标客户长期采用铺平道路。